BioPharma Resources

Drug Trial Radar · NCT06708286

A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)

A Randomized, Blinded, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Adsorbed Cell-free DTP Vaccine (Five-component)

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,820 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,820

Actual

Start

Dec 20, 2024

Primary completion

Jul 1, 2025

Study completion Mar 30, 2026

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
First posted
Nov 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, blinded, controlled phase II and III clinical trial evaluating the immunogenicity and safety of adsorbed cell-free DPT vaccine. 320 subjects aged 7 years and older in the phase II were divided into two age groups, the ≥18 years group and the 7-17 years group, and randomized 3:1 to receive the trial vaccine Tdcp versus the control vaccine PPV23. 1500 subjects in the phase III were divided into 3 age subgroups. 780 subjects were planned to be enrolled in the 6-year-old group and randomized 1:1 to receive the experimental vaccine Tdcp versus the control vaccine DTaP, and 360 subjects were planned to be enrolled in each of the 7-17 and ≥18 age groups and randomized 3:1 to receive the experimental vaccine Tdcp versus the control vaccine PPV23.

Conditions

  • Diphtheria
  • Tetanus
  • Pertussis

Interventions

  • Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp))Biological

    1 dose of Tdcp vaccine (0.5ml) on day 0

  • 23-valent Pneumococcal Polysaccharide Vaccine (PPV23)Biological

    1 dose of PPV23 vaccine (0.5ml) on day 0

  • TdcpBiological

    1 dose of Tdcp vaccine (0.5ml) on day 0

  • PPV23Biological

    1 dose of PPV23 vaccine (0.5ml) on day 0

  • TdcpBiological

    1 dose of Tdcp vaccine (0.5ml) on day 0

  • PPV23Biological

    1 dose of PPV23 vaccine (0.5ml) on day 0

  • TdcpBiological

    1 dose of Tdcp vaccine (0.5ml) on day 0

  • PPV23Biological

    1 dose of PPV23 vaccine (0.5ml) on day 0

  • TdcpBiological

    1 dose of Tdcp vaccine (0.5ml) on day 0

  • Diphtheria-tetanus-acellular pertussis vaccine (DTaP)Biological

    1 dose of DTaP vaccine (0.5ml) on day 0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase II: Incidence of adverse reactionsTime frame: Within 0-30 days after vaccination
  2. Phase III: Geometric mean concentration (GMC) of serum anti-PT, FHA, PRN, FIM 2&3, DT, TT antibodiesTime frame: Pre-vaccination and 30 days post-vaccination
  3. Phase III: Proportion of serum anti-DT and TT antibodies ≥ 0.1IU/mlTime frame: 30 days after vaccination
  4. Phase III: Incidence of adverse reactionsTime frame: Within 0-30 days after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kaihua County Center for Disease Control and Prevention

    Kaihua, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.